Abstract 103P
Background
Colorectal cancer (CRC) among young individuals less than 50 years old has been increasing worldwide. This study aims to investigate clinicopathologic characteristics of colorectal cancers (=<50 years versus more than 50 years), their correlation with the outcome in both categories and overall survival in both.
Methods
A retrospective analysis of colorectal adenocarcinoma at King Abdullah Medical City between 2015 - 2021. Demographic, staging, and treatment exposure. Overall survival among (≤ 50 years ) versus (>50 years ).
Results
Overall, 556 patients were treated: (57%) were male, ≤ 50 years (21%), more than half of the participants were either overweight (28%) or obese (29%). Early stage (357,64%) and stage IV(199,35%),left-sided colon cancer represent (416, 74%), right-sided (140, 25.2%), adenocarcinoma (500,90%), and the rest Mucinous, Signet ring and other (10%). Common metastatic sites are lung (78%), peritoneum (47,9%) and Liver metastasis (151, 27%). RAS wild was (13%) BRAF mutation (2%). Curative surgery was done for (67%) and palliative surgery (11%). Patients received adjuvant treatment (44%), XELOX (29%) followed by capecitabine (10%) and FOLFOX (5%) for three months (21%) and six months (23%). Metastatic setting therapy, first-line XELOX (18%), XELOX with Cetuximab (5%), and XELOX with Bevacizumab (4%). Common second-line treatment FOLFIRI/XELIRI with bevacizumab accounting for (16%). Beyond the second line, TAS-102 (6%) followed by regorafenib (0.4%). Multivariable analysis to compare the two age groups( ≤ 50) (>50) no difference in the occurrence of (I, II, III) (73,62%) versus (284,65%), metastatic disease (44 %) versus (35%), tumor sidedness (left versus right )90 (76%)27 (23%) versus 326(74.94%) 113(25.06 %) respectively. Regardless of age categories ≤ 50 or >50 years, there was no difference in overall survival with a median of 13 months (≤ 50 ) and 13.5 months for (>50 ).
Conclusions
The majority of CRC aged more than 50, and multivariable were comparable between the age groups in term of high BMI, stage at diagnosis, and tumor sidedness. Based on our analysis age is not considered poor prognostic factor larger studies are needed to explore this factor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.